Results 21 to 30 of about 4,520 (170)

Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review

Health Technology Assessment in Action, 2022
Context: In the first stage of viral replication, COVID-19 may cause a remarkable inflammatory response in patients. Paxlovid is an oral antivirus medicine that functions through the inhibition of one of the essential enzymes to viral replication, called
Mohamad Reza Mobinizadeh, Ali Akbarisari, Alireza Olyaeemanesh, Marita Mohammadshahi, Elham Ahmadnezhad, Parisa Aboee, Zahra Gharib Naseri, Zeinab Fakoorfard, Raheleh Sadeghi   +8 more
doaj   +1 more source

Ranolazine Toxicity Secondary to Paxlovid

Cureus, 2023
An Emergency Use Authorization (EUA) was issued by the FDA on December 22, 2021 for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid - Pfizer) for outpatient treatment of mild to moderate COVID-19 in children 12 years and old that are high risk of severe disease.
Casey, Bradley, Vernick, Robert C, Bahekar, Amol, Patel, Divyang, Ncogo Alene, Inmaculada   +4 more
openaire   +2 more sources

Posterior Reversible Encephalopathy Syndrome in an Older Patient in the COVID-19 and Paxlovid Era

Annals of Internal Medicine: Clinical Cases, 2023
Nirmatrelvir/ritonavir (Paxlovid) has been prescribed increasingly for treatment of COVID-19. Due to ritonavir's inhibition of CYP3A4, there are many medication interactions to consider.
Katharine Rosiene, Minisha Lohani, Mario Gemmato-Valecillos, Cristina Marti-Amarista, Sadia Abbasi   +4 more
doaj   +1 more source

Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: A case report with a literature review

Frontiers in Psychiatry, 2022
BackgroundSchizophrenia is considered one of the major risk factors for mortality from SARS-CoV-2 infection. Early antiviral treatment is important to decrease the risk of mortality.
Chun-I Liu, Kah Kheng Goh, Kah Kheng Goh, Kah Kheng Goh, Chun-Hsin Chen, Chun-Hsin Chen, Chun-Hsin Chen   +6 more
doaj   +1 more source

Paxlovid–tacrolimus drug–drug interaction caused severe diarrhea that induced combined diabetic ketoacidosis and a hyperglycemic hyperosmolar state in a kidney transplant patient: a case report

Journal of Medical Case Reports, 2023
Background Transplant recipients are at high risk of coronavirus disease 2019, and a timely supply of antivirals should be prioritized for those patients.
Wei Luo, Yu He, Mao Gang Wei, Guang Bing Lu, Qun Yi   +4 more
doaj   +1 more source

Risks of paxlovid in a heart transplant recipient

The Journal of Heart and Lung Transplantation, 2023
The burden of morbidity and mortality from SARS-CoV-2 infection is especially significant in heart transplant patients who are at higher risk for poor outcomes owing to immunosuppression, blunted response to vaccination, and multiple comorbid conditions.
Kristin Stawiarski, Robin Avery, Sara Strout, Priya Umapathi   +3 more
openaire   +2 more sources

A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses. [PDF]

Adv Sci (Weinh)
Cryopreserved lung‐humanized mice overcome the dependency to fresh tissues and permit head‐to‐head profiling of all four human common cold coronaviruses versus SARS‐CoV‐2 infection; the model validates Paxlovid efficacy against HKU1 and, when coupled with human immune‐system engraftment, enables interrogation of lung‐resident human immunity and HKU1 ...
Cheng C, Sun J, Lu C, Yu Q, He Y, Wu B, Ren D, Ding S, Zhao J, Li Y.   +9 more
europepmc   +2 more sources

Paxlovid-Induced Symptomatic Bradycardia and Syncope

Cureus, 2023
Paxlovid (nirmatrelvir/ritonavir) is a game changer in the fight against COVID-19 due to its ease of administration and significant benefits of reducing progression to severe COVID-19, hospitalization, and death. Cardiac adverse events such as bradycardia and syncope are not known with this medication.
Ganipisetti, Venu M, Bollimunta, Pratyusha, Maringanti, Sriram   +2 more
openaire   +2 more sources

Absolute Risk Reductions in COVID-19 Antiviral Medication Clinical Trials

Pharmacoepidemiology, 2023
COVID-19 antiviral medications approved or authorized for emergency use by the U.S. Food and Drug Administration are reported to have high efficacy in preventing severe illness, hospitalizations, and deaths.
Ronald B. Brown
doaj   +1 more source

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Frontiers in Pharmacology, 2022
Background: Our previous studies have shown that Yindan Jiedu granules (YDJDG) can effectively treat coronavirus disease 2019 (COVID-19); however, the high infectivity and the immune escape potential of the Omicron variant BA.2 make it more difficult to ...
Ying Feng, Yao Liu, Long Liu, Yao Liu, Yuyong Jiang, Yixin Hou, Yang Zhou, Rui Song, Xiaoyou Chen, Xianbo Wang   +9 more
doaj   +1 more source